US2014335129A1PendingUtilityA1

Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins

76
Assignee: NUTRICIA NVPriority: Jun 4, 2010Filed: Jul 21, 2014Published: Nov 13, 2014
Est. expiryJun 4, 2030(~3.9 yrs left)· nominal 20-yr term from priority
Inventors:Léon Mathieu Johannes KnippelsElisabeth Catharina Adriana Maria Van EschJohan Garssen
A23L 33/21A23L 33/19A61K 31/733A61K 31/702A23L 33/185A61K 38/10A61K 38/018A23L 33/40A23L 33/17A23L 33/18A61K 38/17A61K 39/35A61K 2039/577A23V 2002/00A61K 39/0005A23L 1/3056A23L 1/296
76
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods for providing infant nutrition with partially hydrolysed proteins and non-digestible oligosaccharides for use in induction of oral tolerance against native dietary proteins.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for enhancing a partial protein hydrolysate-induced oral immune tolerance against dietary proteins in a subject in need thereof, said method comprising administering to said subject at least one non-digestible oligosaccharide selected from the group consisting of fructo-oligosaccharide, non-digestible dextrin, galacto-oligosaccharide, xylo-oligosaccharide, arabino-oligosaccharide, arabinogalacto-oligosaccharide, gluco-oligosaccharide, glucomanno-oligosaccharide, galactomanno-oligosaccharide, mannan-oligosaccharide, chito-oligosaccharide, uronic acid oligosaccharide, sialyloligosaccharide and fuco-oligosaccharide, wherein the partial protein hydrolysate comprises at least 3 wt % of peptides with a size of 5 kDa or above and at least 50 wt. % of peptides with a size below 5 kDa and wherein the partial protein hydrolysate is partial mammalian milk protein hydrolysate, partial whey protein hydrolysate or partial beta-lactoglobulin hydrolysate. 
     
     
         2 . The method according to  claim 1 , wherein the partial protein hydrolysate comprises at least one beta-lactoglobulin peptide comprising a sequence selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 and SEQ ID NO 4, and wherein the at least one beta-lactoglobulin peptide has a molecular weight below
 5 kDa.   
     
     
         3 . The method according to  claim 1 , wherein the size distribution of the peptides in the partial protein hydrolysate is 60 to 90%<1 kDa, 5 to 20% 1 to <2 kDa, 2 to 16% 2 to <5 kDa, 0.6 to 3% 5 to <10 kDa, 0.5 to 2% 10 to 20 kDa and 1 to 3%>20 kDa, based on dry weight of peptides present in partial protein hydrolysate. 
     
     
         4 . The method according to  claim 1 , wherein the partial protein hydrolysate comprises a ratio of the relative amount (wt %) of peptides with a size from 2 to <5 kDa to the relative amount (wt %) of peptides with a size of at least 5 kDa is (5 to 1):1. 
     
     
         5 . The method according to  claim 1 , wherein the non-digestible oligosaccharide is selected from the group consisting of fructo-oligosaccharide, galacto-oligosaccharide and uronic acid oligosaccharide. 
     
     
         6 . The method according to  claim 1 , wherein the non-digestible oligosaccharide is a mixture of galacto-oligosaccharides, fructo-oligosaccharides and galacturonic acid oligosaccharides. 
     
     
         7 . A method for inducing oral immune tolerance against dietary proteins in a subject in need thereof, said method comprising administering to said subject an enteral composition comprising at least one non-digestible oligosaccharide selected from the group consisting of fructo-oligosaccharide, non-digestible dextrin, galacto-oligosaccharide, xylo-oligosaccharide, arabino-oligosaccharide, arabinogalacto-oligosaccharide, gluco-oligosaccharide, glucomanno-oligosaccharide, galactomanno-oligosaccharide, mannan-oligosaccharide, chito-oligosaccharide, uronic acid oligosaccharide, sialyloligosaccharide and fuco-oligosaccharide and at least one partial protein hydrolysate, the partial protein hydrolysate comprising at least 3 wt. % of peptides with a size of 5 kDa or above and at least 50 wt. % of peptides with a size below 5 kDa and wherein the partial protein hydrolysate is partial mammalian milk protein hydrolysate, partial whey protein hydrolysate or partial beta-lactoglobulin hydrolysate. 
     
     
         8 . The method according to  claim 7 , wherein the composition comprises at least one beta-lactoglobulin peptide comprising a sequence selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 and SEQ ID NO 4, and wherein the at least one beta-lactoglobulin peptide has a molecular weight below 5 kDa. 
     
     
         9 . The method according to  claim 7 , wherein the size distribution of the peptides in the partial protein hydrolysate is 60 to 90%<1 kDa, 5 to 20% 1 to <2 kDa, 2 to 16% 2 to <5 kDa, 0.6 to 3% 5 to <10 kDa, 0.5 to 2% 10 to 20 kDa and 1 to 3%>20 kDa, based on dry weight of peptides present in partial protein hydrolysate. 
     
     
         10 . The method according to  claim 7 , wherein the partial protein hydrolysate comprises a ratio of the relative amount (wt %) of peptides with a size from 2 to <5 kDa to the relative amount (wt %) of peptides with a size of at least 5 kDa is (5 to 1):1. 
     
     
         11 . The method according to  claim 7 , wherein the non-digestible oligosaccharide is selected from the group consisting of fructo-oligosaccharide, galacto-oligosaccharide and uronic acid oligosaccharide. 
     
     
         12 . The method according to  claim 7 , wherein the non-digestible oligosaccharide is a mixture of galacto-oligosaccharides, fructo-oligosaccharides and galacturonic acid oligosaccharides. 
     
     
         13 . The method according to  claim 7 , wherein the enteral composition comprises:
 a) at least 5 wt. % partial whey protein hydrolysate or at least 5 wt.-% of the at least one beta-lactoglobulin peptide, each based on dry weight of the composition and   b) at least 1 wt % of the sum of galacto-oligosaccharides, fructo-oligosaccharides and galacturonic acid oligosaccharides based on dry weight of the composition, wherein the weight ratio of galacto-oligosaccharides:fructo-oligosaccharides: galacturonic acid oligosaccharides is (20-4):(0.5-2):1.   
     
     
         14 . The method according to  claim 7 , wherein the enteral composition comprises a protein component, a lipid component and digestible carbohydrates and wherein the protein component is present in an amount of 5 to 25% based on total calories of the composition. 
     
     
         15 . The method according to  claim 7 , wherein the enteral composition comprises 0.05 to 20 wt. % non-digestible oligosaccharide based on dry weight of the composition. 
     
     
         16 . The method according to  claim 10  wherein, in the enteral composition, the ratio of the relative amount (wt %) of peptides with a size from 2 to <5 kDa to the relative amount (wt %) of peptides with a size of at least 5 kDa is (4 to 1):1. 
     
     
         17 . The method according to  claim 7 , wherein the enteral composition is an infant formula or follow-on-formula. 
     
     
         18 . A method for preventing inflammatory bowel disease in a subject in need thereof, said method comprising administering to said subject an enteral composition comprising at least one non-digestible oligosaccharide selected from the group consisting of fructo-oligosaccharide, non-digestible dextrin, galacto-oligosaccharide, xylo-oligosaccharide, arabino-oligosaccharide, arabinogalacto-oligosaccharide, gluco-oligosaccharide, glucomanno-oligosaccharide, galactomanno-oligosaccharide, mannan-oligosaccharide, chito-oligosaccharide, uronic acid oligosaccharide, sialyloligosaccharide and fuco-oligosaccharide and at least one partial protein hydrolyzate, the partial protein hydrolysate comprising at least 3 wt. % of peptides with a size of 5 kDa or above and at least 50 wt. % of peptides with a size below 5 kDa and wherein the partial protein hydrolysate is partial mammalian milk protein hydrolysate, partial whey protein hydrolysate or partial beta-lactoglobulin hydrolysate. 
     
     
         19 . The method according to  claim 18 , wherein the composition comprises at least one beta-lactoglobulin peptide comprising a sequence selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 and SEQ ID NO 4, and wherein the at least one beta-lactoglobulin peptide has a molecular weight below 5 kDa. 
     
     
         20 . The method according to  claim 18 , wherein the size distribution of the peptides in the partial protein hydrolysate is 60 to 90%<1 kDa, 5 to 20% 1 to <2 kDa, 2 to 16% 2 to <5 kDa, 0.6 to 3% 5 to <10 kDa, 0.5 to 2% 10 to 20 kDa and 1 to 3%>20 kDa, based on dry weight of peptides present in partial protein hydrolysate. 
     
     
         21 . The method according to  claim 18 , wherein the partial protein hydrolysate comprises a ratio of the relative amount (wt %) of peptides with a size from 2 to <5 kDa to the relative amount (wt %) of peptides with a size of at least 5 kDa is (5 to 1):1. 
     
     
         22 . The method according to  claim 18 , wherein the non-digestible oligosaccharide is selected from the group consisting of fructo-oligosaccharide, galacto-oligosaccharide and uronic acid oligosaccharide. 
     
     
         23 . The method according to  claim 18 , wherein the non-digestible oligosaccharide is a mixture of galacto-oligosaccharides, fructo-oligosaccharides and galacturonic acid oligosaccharides. 
     
     
         24 . The method according to  claim 18 , wherein the enteral composition comprises:
 a) at least 5 wt. % partial whey protein hydrolysate or at least 5 wt.-% of the at least one beta-lactoglobulin peptide, each based on dry weight of the composition and   b) at least 1 wt % of the sum of galacto-oligosaccharides, fructo-oligosaccharides and galacturonic acid oligosaccharides based on dry weight of the composition, wherein the weight ratio of galacto-oligosaccharides:fructo-oligosaccharides:galacturonic acid oligosaccharides is (20-4):(0.5-2):1.   
     
     
         25 . The method according to  claim 18 , wherein the enteral composition comprises a protein component, a lipid component and digestible carbohydrates and wherein the protein component is present in an amount of 5 to 25% based on total calories of the composition. 
     
     
         26 . The method according to  claim 18 , wherein the enteral composition comprises 0.05 to 20 wt. % non-digestible oligosaccharide based on dry weight of the composition. 
     
     
         27 . The method according to  claim 21 , wherein, in the enteral composition, the ratio of the relative amount (wt %) of peptides with a size from 2 to <5 kDa to the relative amount (wt %) of peptides with a size of at least 5 kDa is (4 to 1):1. 
     
     
         28 . The method according to  claim 18 , wherein the enteral composition is an infant formula or follow-on-formula.

Join the waitlist — get patent alerts

Track US2014335129A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.